Photrexa

Migraine, Vitamin B complex deficiency, Migraine Disorders + 2 more
Treatment
20 Active Studies for Photrexa

What is Photrexa

Flavin mononucleotideThe Generic name of this drug
Treatment SummaryRiboflavin is a coenzyme found in cells and tissues that is essential for the proper functioning of several oxidative enzymes, including NADH dehydrogenase.
Multi-Vit with Fluorideis the brand name
Photrexa Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Multi-Vit with Fluoride
Flavin mononucleotide
1997
19

When to interrupt dosage

The measure of Photrexa is contingent upon the diagnosed condition, such as prophylaxis of migraine headaches, Migraine and Vitamin B complex deficiency. The dosage amount fluctuates subject to the technique of delivery (e.g. Oral or Solution / drops) demonstrated in the table beneath.
Condition
Dosage
Administration
Migraine
5.0 mg, , 15.0 mg, 0.6 mg/mL, 2.0 mg/mL, 1.4 mg/mL, 1.56 mg/mL, 1.46 mg/mL, 0.36 mg/mL, 3.6 mg/mL, 2.0 mg, 1.4 mg, 40.0 mg, 14.0 mg, 1.6 mg, 0.0016 mg/mg, 0.625 mg/mL, 10.0 mg/mL, 2.5 mg/mL, 0.2 mg/mL, 0.14 mg/mL, 0.07 mg/mL, 5.0 mg/mL, 0.7 mg/mL, 0.75 mg/mL, 0.25 mg/mL, 0.5 mg/mL, 0.72 mg/mL, 6.0 mg/mL, 0.427 mg/mL, 0.18 mg/mL, 7.5 mg/mL, 0.1 mg/mL, 50.0 mg/mL, 0.4 mg/mL
, Oral, Elixir, Elixir - Oral, Tablet, Tablet - Oral, Tablet, effervescent, Tablet, effervescent - Oral, Capsule, Capsule - Oral, Intramuscular; Intravenous, Injection, solution, Injection, solution - Intramuscular; Intravenous, Injection, Injection - Intramuscular; Intravenous, Injection - Intravenous, Intravenous, Solution / drops, Solution / drops - Oral, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Ophthalmic, Kit, Kit - Ophthalmic, Liquid, Liquid - Oral, Solution, Solution - Oral, Injection, solution - Intravenous, Solution / drops - Ophthalmic, Liquid - Intramuscular; Intravenous, Solution - Intramuscular; Intravenous, Liquid; Tablet, Liquid; Tablet - Oral, Liquid - Intravenous, Syrup, Syrup - Oral, Powder, for solution, Powder, for solution - Intravenous, Capsule; Liquid, Capsule; Liquid - Oral, Powder, Powder - Oral
Vitamin B complex deficiency
5.0 mg, , 15.0 mg, 0.6 mg/mL, 2.0 mg/mL, 1.4 mg/mL, 1.56 mg/mL, 1.46 mg/mL, 0.36 mg/mL, 3.6 mg/mL, 2.0 mg, 1.4 mg, 40.0 mg, 14.0 mg, 1.6 mg, 0.0016 mg/mg, 0.625 mg/mL, 10.0 mg/mL, 2.5 mg/mL, 0.2 mg/mL, 0.14 mg/mL, 0.07 mg/mL, 5.0 mg/mL, 0.7 mg/mL, 0.75 mg/mL, 0.25 mg/mL, 0.5 mg/mL, 0.72 mg/mL, 6.0 mg/mL, 0.427 mg/mL, 0.18 mg/mL, 7.5 mg/mL, 0.1 mg/mL, 50.0 mg/mL, 0.4 mg/mL
, Oral, Elixir, Elixir - Oral, Tablet, Tablet - Oral, Tablet, effervescent, Tablet, effervescent - Oral, Capsule, Capsule - Oral, Intramuscular; Intravenous, Injection, solution, Injection, solution - Intramuscular; Intravenous, Injection, Injection - Intramuscular; Intravenous, Injection - Intravenous, Intravenous, Solution / drops, Solution / drops - Oral, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Ophthalmic, Kit, Kit - Ophthalmic, Liquid, Liquid - Oral, Solution, Solution - Oral, Injection, solution - Intravenous, Solution / drops - Ophthalmic, Liquid - Intramuscular; Intravenous, Solution - Intramuscular; Intravenous, Liquid; Tablet, Liquid; Tablet - Oral, Liquid - Intravenous, Syrup, Syrup - Oral, Powder, for solution, Powder, for solution - Intravenous, Capsule; Liquid, Capsule; Liquid - Oral, Powder, Powder - Oral
Migraine Disorders
5.0 mg, , 15.0 mg, 0.6 mg/mL, 2.0 mg/mL, 1.4 mg/mL, 1.56 mg/mL, 1.46 mg/mL, 0.36 mg/mL, 3.6 mg/mL, 2.0 mg, 1.4 mg, 40.0 mg, 14.0 mg, 1.6 mg, 0.0016 mg/mg, 0.625 mg/mL, 10.0 mg/mL, 2.5 mg/mL, 0.2 mg/mL, 0.14 mg/mL, 0.07 mg/mL, 5.0 mg/mL, 0.7 mg/mL, 0.75 mg/mL, 0.25 mg/mL, 0.5 mg/mL, 0.72 mg/mL, 6.0 mg/mL, 0.427 mg/mL, 0.18 mg/mL, 7.5 mg/mL, 0.1 mg/mL, 50.0 mg/mL, 0.4 mg/mL
, Oral, Elixir, Elixir - Oral, Tablet, Tablet - Oral, Tablet, effervescent, Tablet, effervescent - Oral, Capsule, Capsule - Oral, Intramuscular; Intravenous, Injection, solution, Injection, solution - Intramuscular; Intravenous, Injection, Injection - Intramuscular; Intravenous, Injection - Intravenous, Intravenous, Solution / drops, Solution / drops - Oral, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Ophthalmic, Kit, Kit - Ophthalmic, Liquid, Liquid - Oral, Solution, Solution - Oral, Injection, solution - Intravenous, Solution / drops - Ophthalmic, Liquid - Intramuscular; Intravenous, Solution - Intramuscular; Intravenous, Liquid; Tablet, Liquid; Tablet - Oral, Liquid - Intravenous, Syrup, Syrup - Oral, Powder, for solution, Powder, for solution - Intravenous, Capsule; Liquid, Capsule; Liquid - Oral, Powder, Powder - Oral
Avitaminosis
5.0 mg, , 15.0 mg, 0.6 mg/mL, 2.0 mg/mL, 1.4 mg/mL, 1.56 mg/mL, 1.46 mg/mL, 0.36 mg/mL, 3.6 mg/mL, 2.0 mg, 1.4 mg, 40.0 mg, 14.0 mg, 1.6 mg, 0.0016 mg/mg, 0.625 mg/mL, 10.0 mg/mL, 2.5 mg/mL, 0.2 mg/mL, 0.14 mg/mL, 0.07 mg/mL, 5.0 mg/mL, 0.7 mg/mL, 0.75 mg/mL, 0.25 mg/mL, 0.5 mg/mL, 0.72 mg/mL, 6.0 mg/mL, 0.427 mg/mL, 0.18 mg/mL, 7.5 mg/mL, 0.1 mg/mL, 50.0 mg/mL, 0.4 mg/mL
, Oral, Elixir, Elixir - Oral, Tablet, Tablet - Oral, Tablet, effervescent, Tablet, effervescent - Oral, Capsule, Capsule - Oral, Intramuscular; Intravenous, Injection, solution, Injection, solution - Intramuscular; Intravenous, Injection, Injection - Intramuscular; Intravenous, Injection - Intravenous, Intravenous, Solution / drops, Solution / drops - Oral, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Ophthalmic, Kit, Kit - Ophthalmic, Liquid, Liquid - Oral, Solution, Solution - Oral, Injection, solution - Intravenous, Solution / drops - Ophthalmic, Liquid - Intramuscular; Intravenous, Solution - Intramuscular; Intravenous, Liquid; Tablet, Liquid; Tablet - Oral, Liquid - Intravenous, Syrup, Syrup - Oral, Powder, for solution, Powder, for solution - Intravenous, Capsule; Liquid, Capsule; Liquid - Oral, Powder, Powder - Oral
Iron Deficiency Anemia
5.0 mg, , 15.0 mg, 0.6 mg/mL, 2.0 mg/mL, 1.4 mg/mL, 1.56 mg/mL, 1.46 mg/mL, 0.36 mg/mL, 3.6 mg/mL, 2.0 mg, 1.4 mg, 40.0 mg, 14.0 mg, 1.6 mg, 0.0016 mg/mg, 0.625 mg/mL, 10.0 mg/mL, 2.5 mg/mL, 0.2 mg/mL, 0.14 mg/mL, 0.07 mg/mL, 5.0 mg/mL, 0.7 mg/mL, 0.75 mg/mL, 0.25 mg/mL, 0.5 mg/mL, 0.72 mg/mL, 6.0 mg/mL, 0.427 mg/mL, 0.18 mg/mL, 7.5 mg/mL, 0.1 mg/mL, 50.0 mg/mL, 0.4 mg/mL
, Oral, Elixir, Elixir - Oral, Tablet, Tablet - Oral, Tablet, effervescent, Tablet, effervescent - Oral, Capsule, Capsule - Oral, Intramuscular; Intravenous, Injection, solution, Injection, solution - Intramuscular; Intravenous, Injection, Injection - Intramuscular; Intravenous, Injection - Intravenous, Intravenous, Solution / drops, Solution / drops - Oral, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Ophthalmic, Kit, Kit - Ophthalmic, Liquid, Liquid - Oral, Solution, Solution - Oral, Injection, solution - Intravenous, Solution / drops - Ophthalmic, Liquid - Intramuscular; Intravenous, Solution - Intramuscular; Intravenous, Liquid; Tablet, Liquid; Tablet - Oral, Liquid - Intravenous, Syrup, Syrup - Oral, Powder, for solution, Powder, for solution - Intravenous, Capsule; Liquid, Capsule; Liquid - Oral, Powder, Powder - Oral

Photrexa Novel Uses: Which Conditions Have a Clinical Trial Featuring Photrexa?

66 active studies are now examining the potential of Photrexa in managing Iron deficiency anemia, Vitamin B complex deficiency and other Vitamin Deficiencies.
Condition
Clinical Trials
Trial Phases
Avitaminosis
1 Actively Recruiting
Not Applicable
Migraine
51 Actively Recruiting
Phase 4, Not Applicable, Phase 1, Phase 3, Phase 2, Early Phase 1
Migraine Disorders
1 Actively Recruiting
Phase 3
Iron Deficiency Anemia
7 Actively Recruiting
Phase 3, Phase 4, Phase 2, Not Applicable
Vitamin B complex deficiency
0 Actively Recruiting

Patient Q&A Section about photrexa

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is the cost of Photrexa?

"The manufacturer of a corneal cross-linking system (and the associated riboflavin formulas) has caused controversy by increasing the price of these products from $595 to $2,850."

Answered by AI

What is Photrexa?

"Photrexa is an eye drop that is designed to be used in conjunction with the KXL System. The KXL System is a machine that treats two eye conditions - progressive keratoconus and corneal ectasia as a result of surgery. These conditions can develop when the cornea, which is a part of the eye, becomes too thin. This can lead to vision problems."

Answered by AI

What is Photrexa viscous?

"The medication Photrexa Viscous and Photrexa are photo enhancers that are used in conjunction with the KXL System. This system is used to treat progressive keratoconus and corneal ectasia that has developed following refractive surgery."

Answered by AI

Clinical Trials for Photrexa

Image of Johns Hopkins Medicine in Baltimore, United States.

Embolization for Migraine

18 - 80
All Sexes
Baltimore, MD
This study is to test the safety and feasibility of a procedure called embolization of the middle meningeal arteries (MMA), using a product called Onyx. Embolization creates a plug in the arteries. MMA embolization with Onyx is not approved for use in patients with migraines, but is currently used in patients with subdural hematomas. The FDA is allowing the use of Onyx in this study. It is thought that by using Onyx to block the middle meningeal arteries, the amount of migraine-causing substances which are released into the brain's bloodstream will be reduced. The company that manufactures Onyx, Medtronic, is providing the supplies for this study. Participants will be in the study for about 8 months after enrolling, including 6 months of follow up after the procedure. The participants will be asked to complete a daily headache diary and continue the participant's regular migraine medications. Participants will also have several clinic visits and be asked to provide blood samples for research.
Waitlist Available
Has No Placebo
Johns Hopkins MedicineRisheng Xu, MD, PhDMedtronic
Image of Madigan Army Medical Center in Tacoma, United States.

Vitamin D3 + K2 for Vitamin Deficiency

18 - 69
All Sexes
Tacoma, WA
The main purpose of this research study is to learn about the effects of supplemental vitamin D3 and vitamin K2 on blood levels and the gut microbial community, called the gut microbiome. There are many influences on blood levels of vitamin D and K to include your dietary intake, lifestyle behaviors (physical activity, sleep), genetic alterations in metabolism of these vitamins, and the gut microbial abundance and diversity. You will be asked to take one capsule containing vitamin D3 (125 mcg), vitamin K2 (180 mcg), a combination of vitamins D3 and K2 (same doses as previous), or a placebo powder for 90 days. You will also be asked to complete questionnaires, undergo body composition and blood pressure measurements, provide blood samples and a stool swab, all on 2 occasions about 3 - 4 months apart. By conducting this study, we aim to identify the frequency of common genetic alterations in vitamins D and K metabolism and establish the impact on the gut microbiome for the first time. Your participation in this study will last about 4 - 6 months and include up to 3 visits.
Recruiting
Paid Trial
Madigan Army Medical CenterMary S McCarthy, PhD
Image of University of the Fraser Valley in Chilliwack, Canada.

Mind-Body App + Movement Program for Chronic Pain

19 - 75
All Sexes
Chilliwack, Canada
The investigators are evaluating the effects of a mind-body mobile application, in combination with a guided movement program, on the experience of chronic pain. Participants meeting the criteria for chronic/persistent pain (confirmed via self-report) will complete an online baseline questionnaire. Eligible participants will take part in an intervention that involves use of a 6-week free trial of a mind-body focused mobile application in combination with virtual asynchronous audio-guided somatic education sessions (gentle movement). External data from a usual care control arm and a mobile-app-only arm from a previous study by the same research team, National Clinical Trials (NCT) registry number NCT05090683, will be used for comparison with the current combined intervention. All participants will complete online surveys at the start of the study and after 6 weeks to measure pain intensity and interference (primary outcomes), mental health outcomes (depression, anxiety, stress), pain-related thoughts (pain catastrophizing), quality of life, and fear of movement (secondary outcomes). From weeks 2 to 6, participants will fill out weekly surveys to track how often they engage with each: the somatic education (gentle movement) program and the mobile app. Participants will also complete a follow-up survey at 12 weeks (6 weeks post-intervention conclusion).
Waitlist Available
Has No Placebo
University of the Fraser ValleyCynthia J Thomson, PhD
Image of Centre hospitalier affilié universitaire régional de Trois-Rivières in Trois-Rivières, Canada.

Endoscopic Evaluation for Iron-Deficiency Anemia

18 - 90
All Sexes
Trois-Rivières, Canada
This is a single-center, randomized pilot study evaluating the feasibility and safety of two management strategies for patients on antithrombotic therapy who present with obscure gastrointestinal bleeding (OGIB). Participants will be randomized to either repeated endoscopic evaluations or a conservative medical approach with limited testing. The study aims to assess whether conservative management yields similar clinical outcomes and quality of life compared to standard repeated endoscopic procedures. Results will inform the design of a larger trial and address the current lack of guidelines for managing recurrent iron-deficiency anemia in this patient population.
Recruiting
Has No Placebo
Centre hospitalier affilié universitaire régional de Trois-RivièresÉva Mathieu, PhD
Have you considered Photrexa clinical trials? We made a collection of clinical trials featuring Photrexa, we think they might fit your search criteria.Go to Trials
Image of Mount Sinai Hospital in New York, United States.

Rimegepant + Zavegepant for Migraine

18+
All Sexes
New York, NY
This study evaluates the effectiveness of rimegepant 75 mg orally disintegrating tablet (ODT) single-dose or zavegepant 10 mg nasal spray single-dose as acute migraine treatments during Emergency Department (ED) encounters. Although these two calcitonin gene-related peptide receptors (CGRP) receptor antagonists are FDA-approved for the indication of acute migraine treatment, past studies have been limited to the outpatient setting. If these medications are effective in the Emergency Department, their delivery methods alone may have advantages over intravenous medications commonly used for acute migraine in EDs, including quicker time to treatment delivery, faster pain relief, and reduced ED length of stay. This investigation is a pilot study to examine rimegepant and zavegepant in an ED, to gain insight on effectiveness in this setting. This study will administer rimegepant 75 mg ODT single-dose or zavegepant 10 mg nasal spray single-dose as acute migraine treatments to 100 patients in the Emergency Department. It is a single center, open-label, non-controlled 2-group clinical trial (allocated 1:1 to rimegepant or zavegepant via pseudo-random assignment). The study will enroll adults in the ED meeting ICHD-3 criteria for migraine or probable migraine, with or without aura.
Phase 4
Recruiting
Mount Sinai HospitalJonathan SchimmelPfizer
Image of University of Minnesota in Minneapolis, United States.

Visual Adaptation for Visual Snow

18 - 60
All Sexes
Minneapolis, MN
The goal of this study is to learn more about the brain pathways and activity involved in creating Visual Snow Syndrome (VSS). The main questions it aims to answer are: * Does VSS arise from spontaneous activity in brain pathways? * Where in the brain does the activity contributing to VSS arise? * How does brain activity contribute to VSS? Participants will: 1. Undergo assessments and questionnaires to understand visual and mental symptoms, cognitive, and sensory function. 2. Make visual judgements based on images presented to them both inside and outside a magnetic resonance imaging (MRI) machine. 3. Undergo scanning of their brain while inside of an MRI machine.
Recruiting
Paid Trial
University of MinnesotaMichael-Paul Schallmo, Ph.D.
Image of HCA Florida north florida Hospital in Gainesville, United States.

Bupivacaine Injection for Headache

18+
All Sexes
Gainesville, FL
Headache is a frequent chief complaint among patients presenting to the Emergency Department (ED), accounting for 2.1 million visits annually in the United States. Often, individuals resort to ED care only after over-the-counter or home remedies have failed, leading to the predominant use of intravenous (IV) medications in the ED, including NSAIDs, triptans, neuroleptics, antiepileptics, and dopaminergic antagonists. Unfortunately, these pharmacologic treatments frequently induce side effects such as cognitive impairment, extrapyramidal reactions, and the potential for medication dependency. In the ED, patients frequently require concurrent administration of multiple systemic medications to achieve satisfactory pain relief, thereby elevating the risk associated with medication use. Despite these medication regimens, a significant portion of patients continue to experience inadequate pain relief. Consequently, the search for an optimal headache therapy-characterized by rapid and effective pain relief, long lasting results, minimal side effects, and allows for rapid ED patient turnover-continues to be a popular area of research in emergency medicine. The investigators plan to evaluate the use of 0.5% bupivacaine cervical IM injection at the c6-7 location for the treatment of non traumatic headaches using a non-inferiority design, randomized, prospective, open-label, controlled trial comparing it to physicians choice of intravenous medications in treatment of headache in the Emergency Department at North Florida Hospital.
Phase 3
Waitlist Available
HCA Florida north florida HospitalRobyn Hoelle, MD
Have you considered Photrexa clinical trials? We made a collection of clinical trials featuring Photrexa, we think they might fit your search criteria.Go to Trials
Image of Brigham and Women's Hospital in Boston, United States.

Cocoa Extract for Migraine

18+
All Sexes
Boston, MA
The goal of this clinical trial is to assess the feasibility of recruitment and adherence to a high-dose cocoa extract supplement in individuals diagnosed with episodic migraine. The main questions it aims to answer are: * Will we be able to enroll 114 participants during the recruitment period? * Will participants take study pills daily during the pill-taking period? Researchers will compare two doses of cocoa extract to placebo to determine the acceptability of higher doses of cocoa extract supplementation in this patient population. Participants will be asked to: * Provide two urine samples * Complete daily questionnaires * Take four study pills a day for 12 weeks
Recruiting
Dietary Supplement
Brigham and Women's HospitalPamela M Rist, ScD
Have you considered Photrexa clinical trials? We made a collection of clinical trials featuring Photrexa, we think they might fit your search criteria.Go to Trials
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security